Investing.com - NewAmsterdam Pharma (NASDAQ: NAMS) reported fourth quarter EPS of $-0.618, $0.01 worse than the analyst estimate of $-0.604. Revenue for the quarter came in at $2.17M versus the consensus estimate of $1.91M.
NewAmsterdam Pharma's stock price closed at $24.230. It is up 150.050% in the last 3 months and up 81.590% in the last 12 months.
NewAmsterdam Pharma saw positive EPS revisions and negative EPS revisions in the last 90 days. See NewAmsterdam Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, NewAmsterdam Pharma's Financial Health score is "good performance".
Check out NewAmsterdam Pharma's recent earnings performance, and NewAmsterdam Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar